Document:

exv10w12

 

Exhibit 10.12

[BioTrove Logo]

BioTrove, Inc.

12 Gill Street, Suite 4000

Woburn, MA 01801-1728

tel: 781 721 3600 fax: 781 721 3601

October 9th, 2007

Mr. Jeffrey Leathe

1060 State Road

Eliot, Maine 03903

Dear Jeff,

This letter confirms the verbal offer that I presented to you on October 4th to join
BioTrove as Senior Vice President and its Chief Financial Officer reporting directly to me. You
will be responsible for all Company financial matters and are expected to build the financial team
in support of a planned public offering anticipated during 2008. The base salary for this position
will be $275,000 per year and is paid bimonthly. You will be eligible to participate in BioTrove’s
bonus program at the current maximum participation level of 30% This program is structured around
the Company’s MBO objectives and your contribution to the Company’s overall performance. A common
stock equity option award of 205,567 shares that equates to 1% of the fully diluted shares of the
Company will be granted to you upon your acceptance of this offer. This grant will have a special
provision wherein 25% of the grant will vest upon BioTrove’s successful public offering. The
remaining options will vest over a 4 year interval as follows: On the first anniversary on your
hiring, 25% of the non vested original grant will vest. At that time one half of your original
grant will be vested assuming an IPO occurred within this one year interval. Vesting of the
remaining options will then occur monthly over the remaining three year grant period.

Consistent with the direction of BioTrove’s Compensation Committee, you will have a non-cause
severance that offers full base salary continuation of up to 12 months. This severance has the
important feature of immediate vesting of all non vested shares you hold at the time of
termination. This feature includes a change of control provision that will survive the contemplated
IPO. All ‘C’ level officers will share this severance plan which we are targeting to put into place
during October. This plan is designed to provide appropriate incentive for the Leadership Team in
the event that an M&A event is elected as the best path forward for BioTrove. You will be eligible
for BioTrove’s generous benefit plan including life, health, dental and disability insurance. This
plan additionally includes a 401K plan with partial Company matching. Susan Melillo Human Resources
Manager (781-721-3614) can brief you on the details.

The above cited compensation has been reviewed and approved by the Compensation Committee Chaired
by Mr. Joshua Phillips. You have also been verbally approved by BioTrove’s Audit Committee chaired
by Mr. Edward Erickson. If you accept this offer, BioTrove’s full board must then approve your
election as an officer of the Corporation.

 

 

Please note that our board has been thoroughly briefed on your candidacy and you have either
personally met or had phone contact with all but Dr. Brenan and Dr. Critchfield. Both individuals
have been briefed by me. Once elected as an officer, you will be covered by BioTrove’s D&O
insurance.

BioTrove is poised for great accomplishments and requires your financial leadership to realize its
future plans. We have assembled a world-class management team that I believe you will find highly
rewarding to work with. I am please to be able to offer you this crucial position and look forward
to working with you to build our Company.

This offer will expire on October 23, 2007.

Sincerely yours,

Albert A. Luderer, PhD

President, CEO and Director

BioTrove Incorporated

12 Gill Street, Suite 4000

Woburn, MA 01801exv10w13

 

Exhibit 10.13

BIOTROVE, INC.

EMPLOYMENT AGREEMENT

     THIS EMPLOYMENT AGREEMENT dated as of December 5, 2007 (the “Effective Date”) by and between
BioTrove, Inc. with a mailing address at 12 Gill Street, Suite 4000, Woburn MA 01801-1728 (the
“Company”) and Robert Ellis with a mailing address set forth under the Executive’s name on the
signature line (the “Executive”).

RECITALS

     A. The Company is engaged in the business of researching, developing, manufacturing,
commercializing, providing service and selling systems and technologies for use in the field of
pharmaceutical drug discovery, biotechnology, materials discovery and molecular diagnostics (the
“Business”).

     B. The Company and the Executive desire to enter into this Agreement to reflect the terms and
conditions on which the Executive is employed by the Company.

     NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged the Company and the Executive hereby agree as follows:

1. Term. The Company agrees to employ the Executive, and the Executive agrees to accept such
employment, on the terms and conditions hereinafter as an at will employee. As an at-will employee,
subject to the terms and conditions hereof, the Company may terminate the Executive’s employment at
any time and for any reason or no reason. While employed by the Company, the terms and conditions
of the Executive’s employment shall be governed by this Agreement. The period in which the
Executive is employed shall be referred to herein as the “Term”.

2. Capacity. The Executive shall be employed as Executive Chairman of the Company. In such
capacity, the Executive shall report to and be subject to the supervision of the President and CEO
of the Company or his designee. The Company shall employ the Executive on a full-time basis and the
Executive shall devote his full time diligent professional efforts to the performance of his duties
as Executive Chairman of the Company. The Executive’s place of employment will be the head office
of the Company. The Executive shall adhere to the business policies of the Company in the
performance of his duties, including without limitation as set forth in the Employee Handbook and
as the Company may otherwise or additionally establish.

3. Compensation and Benefits.

     (a) Base Compensation. The Company shall pay to the Executive a base salary at an annual rate
of US $244,400.00 payable in 24 equal semi-monthly installments of $10,183.33 per calendar month.

 

 

     (b) Compensation Adjustment. The Executive’s annual base salary shall be reviewed annually by
the Board of Directors and may be adjusted upward at the sole discretion of the Company.

     (c) Executive and Other Bonus Plans. The Executive shall be entitled to participate in any
bonus plan approved by the Board of Directors in its sole discretion for Company executives in
general. While there are no guarantees that there will be a bonus plan in any particular year, or
that any bonus plan will be funded at any particular level, the Executive shall participate in any
such plan without discrimination. If a bonus plan is approved for a particular year, the Executive
shall be entitled to an annual bonus in an amount consistent with the existing plan year, with
performance goals to be established by the Board of Directors in good faith upon consultation with
Executive.

     (d) Benefits. The Executive shall have the benefits set forth on Exhibit A. The Executive
shall be entitled to participate in any other benefits program approved by the Board of Directors
for Company executives in general and/or as set forth in the Employee Handbook as adopted by the
Company from time to time. The Executive’s participation in any benefit program shall be at the
same level of employee/employer contribution as has been set for all participants in such plans, in
accordance with applicable law.

     (e) Reimbursement of Expenses. The Company shall promptly reimburse the Executive for all
reasonable and necessary business expenses incurred by the Executive in the furtherance of, and in
connection with, the Business of the Company, including, without limitation, travel, board,
lodging, telephone and postage, in accordance with the Company policies in effect from time to
time. To obtain reimbursement, the Executive shall submit to the Company an itemized statement of
such expenses together with copies of bills and receipts. Notwithstanding the foregoing, the
Company may require additional documentation and/or explanations in order to reimburse the
Executive.

4. Non-Competition.

     (a) Definitions. Certain capitalized terms used in this Section 4 shall have the following
meanings

“Competing Organization” means any person or organization, including the Executive,
engaged in, or that anticipates becoming engaged in, researching, acquiring,
producing, distributing, providing investigating, developing, manufacturing,
marketing, supervising, licensing or commercializing a Competing Product or Service
anywhere in the world.

“Competing Product or Service” means any product, process, or service of any person
or organization other than the Company or any of its subsidiaries, in existence or
under development, (i) which is identical to, substantially the same as, in
competition with, or an adequate substitute for any product, process, or service of
the Company or any of its

2

 

subsidiaries, in existence or under development, or about which the Executive
acquires Confidential Information, and (ii) which is (or could reasonably be
anticipated to be) marketed or distributed or is under development to be marketed
or distributed, as to compete with such product, process or service of the Company
or any of its subsidiaries.

     (b) Employment with a Competing Organization. Notwithstanding the provisions of this Section
4, the Company agrees to permit the Executive to accept employment with a Competing Organization,
provided that the Executive’s duties with that Competing Organization during the twelve (12) month
period after termination of the Executive’s employment with the Company, either directly or
indirectly, do not relate to any Competing Product or Service, and provided that the Executive
shall have delivered to the Company a written statement, confirmed in writing by the Executive’s
prospective employer, describing the Executive’s duties and stating that all such duties will be
wholly unrelated, either directly or indirectly, to any Competing Product or Service and the
Executive will not be required or asked to disclose any Confidential Information of the Company in
the course of the performance of his duties. The term “wholly unrelated” shall mean among other
things that the Executive will not work in, consult with, cooperate with or provide information to
any person, department or business segment of the Competing Organization which is researching,
acquiring, producing, distributing, providing, investigating, developing, manufacturing, marketing,
supervising, licensing or commercializing any Competing Product or Service.

     (c) Stipulations. As a material inducement to the Company’s willingness to employ the
Executive, and in order to protect the Company’s Confidential Information and good will, the
Executive agrees to the following stipulations:

	 	(i)	 	During the Term and for a period of one year after
termination of the Executive’s employment with the Company, the Executive will
not, directly or indirectly, solicit or divert business from any of the
customers or accounts of the Company.
	 
	 	(ii)	 	During the term and for a period of one year after the
Executive’s termination of employment with the Company, the Executive will not
render services, directly or indirectly, as an employee, consultant, director,
advisor or otherwise, to any Competing Organization.
	 
	 	(iii)	 	During the Term and for a period of one year thereafter, the
Executive will not solicit any of the Company’s employees or consultants to
leave the employ of the Company or hire or cause to be hired any person who
was during or for six months after the termination of Executive’s employment
by the Company an employee or consultant of the Company.

5. Disclosure of Developments. The Executive will make full and prompt disclosure to the Company of
all inventions, original works or authorship, improvements,

3

 

modifications, discoveries, creations, methods, processes and developments which are within the
scope of the Company’s actual or reasonably anticipated business and which are made or conceived by
the Executive alone or together with others during the term of his employment, whether or not such
developments are patentable or protected as confidential information, whether or not such
developments are in process or reduced to practice, whether or not such developments are made or
conceived during normal working hours or on or off the premises of the Company (all of which are
hereinafter collectively termed “Developments”), and whether or not such Developments are
assignable to the Company under the provisions of Section 6 below.

6. Assignment of Developments.

     (a) The Executive agrees to assign and hereby assigns to the Company all title, interests and
rights, including, without limitation, intellectual property rights, in and to any and all
Developments, and agrees to assign to the Company any and all patents and patent applications
arising from such Developments, and agrees to execute and deliver such assignments, patents and
patent applications and other documents (including, without limitation, powers of attorney) as the
Company may direct, and agrees to cooperate fully with the Company during the Term, to enable the
Company to secure and maintain rights in said Developments in any and all countries. In the event
that any of such Developments are by operation of applicable state law excluded from this
assignment, the Executive agrees that the Company shall have a non-exclusive, fully paid license to
use for all purposes any such Developments not assigned to the Company under this Section 6. The
Executive understands and agrees that the Company shall determine, in its sole and absolute
discretion, whether an application for patent, copyright, mask work registration, or for any other
intellectual property right shall be filed on any Development which is assigned to the Company
under this Agreement, and whether such application shall be prosecuted or abandoned prior to
issuance or registration.

     (b) If the Company is unable to procure Executive’s signature, within thirty (30) days
following delivery of written request therefor, on any document reasonably necessary to apply for,
prosecute, obtain, or enforce any patent, copyright, trademark or other right or protection
relating to any Development, whether by reason of Executive’s mental or physical incapacity,
Executive’s unavailability, or any other cause whatsoever, then Executive agrees and hereby
irrevocably appoints the Company and each of its duly authorized officers as the Executive’s agent
and attorney-in-fact, to act for and in Executive’s behalf to execute and file any such document
and to do all other lawfully permitted acts to further the prosecution, issuance, and enforcement
of patents, copyrights, or other rights or protections, with the same force and effect as if
executed and delivered by Executive.

7. Copyright. The Executive acknowledges that all works of authorship and all mask works that fall
within the scope of his employment are owned by the Company and are works made for hire.
Accordingly, the Executive agrees to assign and hereby assigns to the Company any and all
copyrights and mask work registration rights, and all other mask work rights in all material
prepared by him during the Term related to the Business.

4

 

8. Confidentiality. During the course of his employment with the Company, the Executive shall have
access to, learn of, or participate in the development of the Company’s confidential information or
confidential information entrusted to the Company by other persons, corporations, or firms. The
Company’s confidential information includes matters not generally known outside of the Company,
such as, assays, nucleic acid sequences, amino acid sequences, vectors, cells, technical data,
methodologies, processes, know-how, trade secrets, experimentation, research and developments
relating to existing and future products and services marketed or used by the Company (whether or
not such products or services are actually realized or pursued by the Company), and also any
information which gives the Company a competitive advantage including, without limitation, data
relating to the general business operations of the Company (e.g., sales, costs, profits,
organizations, customer lists, pricing methods, etc.). The Executive agrees to hold such
information as strictly confidential and not disclose any such confidential information to any
person, corporation, or firm (other than the Company). The Executive further agrees not to make use
of such confidential information except on the Company’s behalf whether or not such information is
produced by his own efforts. These restrictions shall apply to all such information whether
written, oral, magnetic, optical or in any other form. The Executive understands and agrees that
his confidentiality obligations under this Section 8 shall continue both during his employment and
after termination of his employment until such confidential information becomes generally available
to the public through legitimate means. It is understood and agreed that specific information which
the Executive may receive, observe, perceive, create, develop, or learn while an employee of the
Company shall not be deemed to be generally available to the public merely because such specific
information is embraced by more general information that is generally available to the public.

9. Return of Information. Upon termination of his employment or at any time upon the request of the
Company, the Executive agrees to deliver to the Company all records, lab books, drawings,
notebooks, notes, reports, correspondence, documents, computer disks and tapes and other data in
any and all forms (without retaining copies) which pertain to the Company’s confidential
information (whether prepared by the Executive or others) or Developments, and also to return to
the Company any equipment, tools, computers or other devices owned by the Company and in his
possession. The Executive agrees that the above documents, data and devices are the exclusive
property of the Company and shall not be copied or removed from the Company premises except in the
pursuit of the business of the Company.

10. No Conflicts. The Executive hereby represents that he has no present obligation to assign to
any former employer, or any other person, corporation or firm (other than the Company), any
Developments covered by Section 6. The Executive is not subject to any agreement, restriction,
right or interest in anyone limiting in any way the scope of this Agreement or his employment by
the Company or in any way inconsistent herewith. The Executive will not disclose to the Company, or
induce the Company to use, any confidential information of other persons, corporations, or firms
including his present or former employers (if any).

5

 

11. Termination of Employment.

     (a) Change in Control. As used in Sections 11 and 12, a “Change in Control” shall be deemed to
have occurred upon the occurrence of any one of the following events:

	 	(i)	 	any “Person,” as such term is used in Sections 13(d) and
14(d) of the Securities Exchange Act of 1934, as amended (the “Act”) (other
than the Company, any of its subsidiaries, or any trustee, fiduciary or other
person or entity holding securities under any employee benefit plan or trust
of the Company or any of its subsidiaries), together with all “affiliates” and
“associates” (as such terms are defined in Rule 12b-2 under the Act) of such
person, shall become the “beneficial owner” (as such term is defined in Rule
13d-3 under the Act), directly or indirectly, of securities of the Company
representing 50 percent or more of the combined voting power of the Company’s
then outstanding securities having the right to vote in an election of the
Company’s Board of Directors (“Voting Securities”) (in such case other than as
a result of an acquisition of securities directly from the Company); or
	 
	 	(ii)	 	persons who, as of the date hereof, constitute the Company’s
Board of Directors (the “Incumbent Directors”) cease for any reason,
including, without limitation, as a result of a tender offer, proxy contest,
merger or similar transaction, to constitute at least a majority of the Board,
provided that any person becoming a director of the Company subsequent to the
date hereof shall be considered an Incumbent Director if such person’s
election was approved by or such person was nominated for election by either
(A) a vote of at least a majority of the Incumbent Directors or (B) a vote of
at least a majority of the Incumbent Directors who are members of a nominating
committee comprised, in the majority, of Incumbent Directors; but provided
further, that any such person whose initial assumption of office is in
connection with an actual or threatened election contest relating to the
election of members of the Board of Directors or other actual or threatened
solicitation of proxies or consents by or on behalf of a Person other than the
Board, including by reason of agreement intended to avoid or settle any such
actual or threatened contest or solicitation, shall not be considered an
Incumbent Director; or
	 
	 	(iii)	 	the consummation of (A) any consolidation or merger of the
Company where the stockholders of the Company, immediately prior to the
consolidation or merger, would not, immediately after the consolidation or
merger, beneficially own (as such term is defined in Rule 13d-3 under the
Act), directly or indirectly, shares representing in the aggregate more than
50 percent of the voting shares of the Company issuing cash or securities in
the consolidation or merger (or of its ultimate parent corporation, if any),
or (B) any sale, lease, exchange or other transfer (in one

6

 

	 	 	 	transaction or a series of transactions contemplated or arranged by any
party as a single plan) of all or substantially all of the assets of the
Company; or
	 
	 	(iv)	 	the approval by the Company’s stockholders of any plan or
proposal for the liquidation or dissolution of the Company.

     (b) Notwithstanding the provisions of Section 1, the Executive’s employment hereunder shall
terminate under the following circumstances:

          (i) Death or Disability. The Executive’s employment hereunder shall terminate upon his death
or disability (as hereinafter defined). For purposes of this Agreement only, the Executive shall be
deemed disabled if in the opinion of the Board of Directors, determined in good faith relying
specifically on the opinion of a qualified regionally recognized medical doctor (to be chosen by
the Board of Directors) specializing in such alleged disability, the Executive is unable to
substantially perform services hereunder due to illness, injury, accident or condition of either a
physical disability or mental illness for greater than one hundred eighty (180) days in the
aggregate in any twelve (12) month period.

          (ii) Termination by the Company for Cause. The Company may terminate the Executive’s
employment for “Cause” (as hereinafter defined) after seven (7) days’ prior written notice to the
Executive setting forth in reasonable detail the nature of such cause if during such period the
Executive shall not have cured the basis therefor. For the purposes hereof, “Cause” shall be
determined by the Board of Directors of the Company acting in good faith and shall mean any of the
following:

7

 

	 	(A)	 	the conviction of the Executive by a court of competent
jurisdiction of any felony involving dishonesty, breach of trust or
misappropriation or the entering of a plea by the Executive of nolo contendre
thereto;
	 
	 	(B)	 	the commission by the Executive of an act of fraud upon, or
breaching his duty of loyalty to, the Company or any of its subsidiaries;
	 
	 	(C)	 	a conviction for willful violation of any law, rule or
regulation governing the operation of the Company or any of its subsidiaries
which is punishable by imprisonment for six (6) months or more;
	 
	 	(D)	 	the substantial and continuing failure or refusal of the
Employee, after written notice thereof, to reasonably attempt to perform his
or her job duties and responsibilities (other than failure or refusal
resulting from incapacity due to physical disability or mental illness) which
failure or refusal is committed in bad faith and is not in the best interest
of the Company;
	 
	 	(E)	 	a breach by the Executive of Sections 4, 5, 6, 7, 8, 9 or 10
of this Agreement, which breach continues for more than seven (7) days after
written notice has been given to the Executive, such notice setting forth in
reasonable detail the nature of such breach; or
	 
	 	(F)	 	the deliberate and willful disregard of the written rules or
policies of the Company which results in a material and substantial loss,
damage or injury to the Company.

          (iii) Termination Without Cause. The Company may terminate the Executive without Cause at
anytime subject to the terms and conditions hereof.

          (iv) Termination by the Executive for Good Reason. The Executive may terminate his or her
employment with the Company for Good Reason within one year following the occurrence of a Change in
Control. For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the
following events:

	 	(A)	 	a reduction in the Executive’s then-current annual base
salary or bonus opportunity ; or
	 
	 	(B)	 	any failure to offer the Executive’s the same level of
benefits offered to similarly situated employees; or
	 
	 	(C)	 	a significant diminution in the Executive’s duties or
responsibilities; or
	 
	 	(D)	 	the relocation of the Executive’s primary business location
to a location that increases the Executive’s commute by more than fifty

8

 

	 	 	 	(50) miles compared to the commute of the Executive to the Executive’s
then-current primary business location; or
	 
	 	(E)	 	the failure to pay the Executive any portion of his or her
current base salary, bonus or benefits within twenty (20) days of the date
such compensation is due, based upon the payment terms currently in effect; or
	 
	 	(F)	 	the failure of the Company to obtain a reasonably
satisfactory agreement from any successor to assume and agree to perform this
Agreement.

provided that any of the events described in clauses (A), (B), (C), (D), (E) or (F) of this Section
11(b)(iv) shall constitute Good Reason only if the Company fails to cure such event within thirty
(30) days after receipt from the Executive of written notice of the event which constitutes Good
Reason; provided, further, that “Good Reason” shall cease to exist for an event on the sixtieth
(60th) day following its occurrence, unless the Executive has given the Company written notice
thereof prior to such date.

12. Payments Upon Termination of Employment.

     (a) Payments Upon Termination by the Company for Cause; Termination due to Death or Disability
of the Executive or Resignation of the Executive for any reason. If at any time during the Term,
the Company shall terminate the Executive for cause, if the Executive dies or suffers a disability
during the Term or if the Executive resigns for any reason, the Executive shall be entitled to
receive from the Company only such portion of the base salary (determined in accordance with
Section 3(a)) as is accrued and unpaid through the date of such termination. The Executive will
immediately forfeit all then unvested options and unvested restricted stock.

     (b) Payments Upon Termination Without Cause or for Good Reason. If at any time during the Term
the employment of the Executive is terminated without Cause by the Company or the Executive
terminates the Executive’s Employment for Good Reason, then in such case, subject to the Executive
signing the Company’s standard Termination and Release Agreement within 30 days of the date of
termination:

	 	(i)	 	The Company shall continue to pay to the Executive, or to his
personal representative(s) (in case of his death), the Executive’s base salary
in effect just prior to the date of such termination for a period equal to
twelve (12) months after the date of termination (the “Severance Period”)
payable in installments as and when such salary would normally have been paid
as provided in Section 3(a). If the Executive is Employed (as defined below)
with another company as of the end of the first six (6) months Severance
Period, the Company shall no longer be obligated to pay to the Executive the
Executive’s severance payments for the remainder of the Severance Period. In
all cases, severance payments hereunder shall

9

 

	 	 	 	continue only so long as the Executive continues to comply with and not
breach the terms of this Agreement and the Termination and Release
Agreement and in the event of such noncompliance or breach, all severance
payments shall immediately be terminated. For the purposes hereof,
“Employed” includes employment as an employee or engagement as a
consultant, where such engagement is contracted for at least 35 hours per
week for at least three (3) months guaranteed, or the equivalent thereof.
	 
	 	(ii)	 	The Company shall maintain in effect during the Severance
Period, at its sole expense, all group insurance (including life, health,
accident and disability insurance) and, to the extent permitted by applicable
law, all other employee benefit plans, programs or arrangements in which the
Executive was participating at any time during the six (6) month period
preceding such termination provided that this obligation shall terminate as of
the date when then the Company is no longer required to make severance
payments under Section 12(b)(i). During the Severance Period if the Company is
unable to maintain the health insurance plan in which the Executive was
participating or provide the Executive coverage under the health insurance
plan because the Executive is ineligible for coverage under the terms thereof,
the Executive shall be eligible to receive continued group health plan
benefits to the extent authorized by and consistent with 29 U.S.C. § 1161 et
seq. (COBRA), with the cost of the regular premium for such benefits shared in
the same relative proportion by the Executive and the Company as in effect on
the Date of Termination. In all cases, provision of benefits hereunder shall
continue only so long as the Executive continues to comply with and not breach
the terms of this Agreement and the Termination and Release Agreement and in
the event of such noncompliance or breach, all benefits (except as required by
law) shall immediately be terminated.
	 
	 	(iii)	 	All non-vested stock options or restricted stock in the
Company held by the Executive or in a trust established by the Executive for
the benefit of his spouse, children or heirs will continue to vest according
to its applicable schedule during the Severance Period but only so long as the
Executive continues to comply with and not breach the terms of this Agreement
and the Termination and Release Agreement and in the event of such
noncompliance or breach, all then unvested stock options and restricted stock
shall be immediately terminated; provided however that notwithstanding
anything to the contrary in any applicable option agreement or stock-based
award agreement, upon a termination of the Executive without Cause within one
year following a Change of Control of the Company or a Termination by the
Executive for Good Reason, all non-vested stock options or restricted stock in
the Company

10

 

	 	 	 	held by the Executive or in a trust established by the Executive for the
benefit of his spouse, children or heirs shall immediately accelerate and
become exercisable or non-forfeitable as of the effective date of such
termination. It is understood that such continued vesting may disqualify
the shares options from being treated as incentive stock options.
	 
	 	(iv)	 	The Company shall pay to the Executive on the Termination
Date accrued but unused personal time off (PTO) in accordance with the
provisions of the Company’s PTO policy then in effect.

     In the event that the Executive’s participation in any of the foregoing plans, programs or
arrangements contemplated by Clause (ii) of Section 12(b) is barred by law or otherwise, or in the
event that any such plan, program or arrangement is discontinued or the benefits thereunder are
materially reduced during such period, the Company shall provide the Executive with benefits
substantially similar to those to which the Executive was entitled immediately prior to the date of
his termination of employment, to the extent and for the periods specified in this Clause (ii) of
Section 12(b).

     Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s
termination of employment, the Executive is considered a “specified employee” within the meaning of
Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”), and if any
payment that the Executive becomes entitled to under this Agreement is considered deferred
compensation subject to interest and additional tax imposed pursuant to Section 409A(a) of the Code
as a result of the application of Section 409A(a)(2)(B)(i) of the Code, then no such payment shall
be payable prior to the date that is the earliest of (i) six months after the Executive’s Date of
Termination, (ii) the Executive’s death, or (iii) such other date as will cause such payment not to
be subject to such interest and additional tax, and the initial payment shall include a catch-up
amount covering amounts that would otherwise have been paid during the first six-month period but
for the application of this Section 4(d).

     (c) Additional Limitation. In the event that any payment or benefit received or to be received
by Executive in connection with the termination of Executive’s employment (whether pursuant to the
terms of this Agreement or any other plan, arrangement or agreement with the Company, or any person
affiliated with the Company or such person) (collectively “Parachute Payments”) would not be
deductible (in whole or part) as a result of section 280G of the Internal Revenue Code of 1986, as
amended (the “Code”), by the Company, an affiliate or other person making such payment or providing
such benefit, the Company shall use its commercially reasonable efforts to obtain the requisite
shareholder approval necessary to avoid the application of Section 280G of the Code. If after
utilizing such efforts the Company is unable to obtain such approval, at Executive’s election (a)
the Parachute Payments shall be reduced until no portion of the Parachute Payments is not
deductible, or (b) Executive shall pay the excise tax payable pursuant to Section 4999 of the Code
with respect to the excess Parachute Payment (as defined in Section 280G(b) of the Code).

11

 

13. Notices. Any notices, requests, demands and other communications provided for by this Agreement
shall be sufficient if in writing and delivered in person or sent by registered or certified mail,
postage paid, to the Executive at the last address the Executive has filed in writing with the
Company, or, in the case of the Company, to the attention of its President. All such communications
shall be deemed given upon receipt. Any party may by notice in writing to the other parties change
the address to which notices to it or him are to be addressed hereunder.

14. Miscellaneous.

     (a) Indemnification. During the period of his employment hereunder, the Company agrees to
indemnify the Executive in his capacity as an officer and Director of the Company and, to the
extent applicable, each subsidiary of the Company, all to the maximum extent permitted under
Section 145 of the Delaware General Corporation Law.

     (b) Entire Agreement. This Agreement constitutes the entire Agreement between the parties and
may not be changed except by a writing duly executed and delivered by the parties hereto.

     (c) Survival. Except as otherwise provided in this Agreement, the obligations of the Company
and the Executive contained in Sections 4, 5, 6, 7, 8, 9, 10 and 14(a) shall survive the
termination of this Agreement.

     (d) Governing Law. This Agreement is governed by and shall be construed in accordance with the
internal laws of the Commonwealth of Massachusetts. The parties hereby consent to the jurisdiction
of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for
the District of Massachusetts. Accordingly, with respect to any such court action, the Executive
(a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and
(c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with
respect to personal jurisdiction or service of process.

     (e) Enforcement. In view of the substantial harm that will result from the breach by the
Executive of any of the covenants contained in Sections 4, 5, 6, 7, 8 and 9, the parties agree that
such covenants shall be enforced to the fullest extent permitted by law. Accordingly, if, in any
judicial proceeding, a court shall determine that such covenants are unenforceable because they
cover too extensive a geographic area or survive for too long a period of time, or for any other
reason, then the parties intend that such covenants shall be deemed to cover such maximum
geographic area and maximum period of time and shall otherwise be deemed to be limited in such
manner as will permit enforceability by such court. If any term or provision of this Agreement or
the application thereof to any circumstance shall, to any extent, be invalid or unenforceable, the
remainder of this Agreement or the application to other persons and circumstances shall not be
affected thereby and each term and provision hereof shall be enforced to the fullest extent
permitted by law.

12

 

     (f) Remedies. Executive agrees that his breach of any of the provisions of Sections 4, 5, 6,
7, 8 and 9 above will cause irreparable damage to the Company and that the recovery by the Company
of money damages will not alone constitute an adequate remedy for such breach. Accordingly, the
Executive agrees that such provisions may be specifically enforced against it or him, in addition
to any other rights or remedies available to the Company on account of any such breach, and the
Executive hereby waives the defense in any equitable proceeding that there is an adequate remedy at
law for any such breach and agrees that injunctive or other equitable relief will not constitute
any hardship upon the Executive.

     (g) Successors. This Agreement shall be binding upon the respective successors, assigns and
heirs of the parties hereto.

     (h) Legal Fees. The Company shall reimburse the Executive all reasonable and documented legal
fees, costs and expenses incurred by the Executive in contesting or disputing any breach of this
Agreement by the Company or in seeking to obtain or enforce any right or benefit provided by this
Agreement up to but not exceeding $100,000; provided, however, that the Company shall have no such
obligation to reimburse the Executive for such legal fees, costs and expenses unless the final
resolution of such matter is determined by a court of competent jurisdiction to be in the
Executive’s favor.

     (i) Effect on Other Plans. An election by the Executive to resign after a Change in Control
under the provisions of this Agreement shall not be deemed a voluntary termination of employment by
the Executive for the purpose of interpreting the provisions of any of the Company’s benefit plans,
programs or policies. Nothing in this Agreement shall be construed to limit the rights of the
Executive under the Company’s benefit plans, programs or policies except that the Executive shall
have no rights to any severance benefits under any Company severance pay plan. In the event that
the Executive is party to an employment agreement with the Company providing for change in control
payments or benefits, the Executive must elect to receive either the benefits payable under such
other agreement or the benefits payable under this Agreement, but not both. The Executive shall
make such an election in the event of a Change in Control.

[Rest of page intentionally left blank; the next page is the signature page]

13

 

     IN WITNESS WHEREOF, the parties hereto have executed this Agreement as a sealed document on the
date first above written.

	 	 	 	 	 	 	 
	 	 	BIOTROVE, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:

Name:
	 	/s/ Albert A. Luderer
 

Albert A. Luderer, Ph.D.
	 	 
	 

	 	Title:
	 	President and CEO	 	 
	 
	 	 	 	 	 	 
	 	 	/s/ Robert Ellis	 	 
	 	 	 	 	 
	 	 	Robert Ellis	 	 
	 

	 	Address:
	 	212 Miramontes Ave.	 	 
	 

	 	 	 	Half Moon Bay, CA 94019	 	 

14

 

Exhibit A

     1. Personal Time Off. The Executive shall be entitled to four weeks personal time off (PTO)
in each calendar year during the term of the Agreement. Unused PTO can accrue up to, but not
exceed, the limits provided for in the Company’s PTO policy. The Executive shall also be entitled
to all paid holidays recognized by the Company.

     2. Insurance and Other Benefit Plans. The Executive shall be entitled to participate in the
Company’s medical, dental, short term and long term disability, life and accidental death and
dismemberment, and other similar insurance plans as they may exist and be generally available to
the Company’s employees from time to time in accordance with the terms of such plans.

15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]